Results of the NILO-PD (Northwestern University) phase 2 trial of Nilotinib show the drug to be safe & tolerable. Unfortunately, it did not demonstrate any benefit for Parkinson's symptoms or biological measures. Basically, it doesn't have very good BBB penetration. Trials will begin on several other c-Abl inhibitors which appear to have better brain penetration.

There will be a webinar on Dec. 17th where more detail will be provided and questions answered.

Though safe, nilotinib does not show promise for benefit for Parkinson's disease